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http://dx.doi.org/10.1016/j.jmii.2013Objectives: This study was conducted to investigate the correlation between antibiotic con-
sumption and the incidence of health-care-associated infections (HCAIs) caused by
methicillin-resistant Staphylococcus aureus (MRSA) (HCAI-MRSA) and vancomycin-resistant
enterococci (VREs) (HCAI-VREs) at a university hospital in Taiwan during the period from
2000 to 2010.
Methods: Data on annual patient-days and annual consumption (defined daily dose/1000
patient-days) of glycopeptides (vancomycin and teicoplanin), linezolid, fusidic acid, tigecy-
cline, and daptomycin were analyzed. Yearly aggregated data on the number of nonduplicate
clinical MRSA and VRE isolates causing HCAI were collected.of Laboratory Medicine, National Taiwan University Hospital, National Taiwan University College of
tw (P.-R. Hsueh).
an Society of Microbiology. Published by Elsevier Taiwan LLC. All rights reserved.
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Vancomycin-resistant
enterococciResults: Overall, the consumption of teicoplanin and linezolid significantly increased during
the study period. A significant decrease in the incidence of HCAI-MRSA and a significant in-
crease in the incidence of HCAI-VRE were found during the study period. A significant correla-
tion was found between the increased use of teicoplanin and linezolid and the decreased
incidence of HCAI-MRSA. By contrast, positive correlations were found between the consump-
tion of teicoplanin and tigecycline and the incidence of HCAI-VRE.
Conclusion: This study identified various correlations between the consumption of antibiotics
and the incidence of HCAI-MRSA and HCAI-VRE. Strict implementation of infection-control
guidelines and reinforcement of administering appropriate antibiotic agents would be helpful
in decreasing the incidence of MRSA and VRE in hospitals.
Copyright ª 2013, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
The incidence of health-care-associated infection (HCAI)
caused by multidrug-resistant bacteria has gradually risen
during the last decade, especially in immunocompromised
patients.1,2 The most common causative agents of HCAI in
the United States are the Gram-positive bacteria Staphy-
lococcus aureus and Enterococcus.3 Methicillin (oxacillin)-
resistant S. aureus (MRSA) is of particular concern because
patients with MRSA infection tend to have higher mortality
rates, longer hospital stays, and higher health-care-
associated costs than patients with methicillin-susceptible
S. aureus infections.1,4 In addition, DiazGranados et al5
found that the mortality rate among patients with
vancomycin-resistant enterococci (VREs) infection was
significantly higher than that among patients with
vancomycin-susceptible Enterococcus infections. Taiwan is
no exception, and VRE and MRSA infections have become
emerging infectious diseases.6e10
Antibiotic use is one of the risk factors for antibiotic
resistance among bacterial species; however, the nature of
this relationship is complicated. Although several studies
have examined the relationship between antimicrobial
consumption and antibiotic resistance, the findings were
inconsistent, possibly due to differences in resistance pro-
files as well as due to differences in antibiotic-prescribing
practices in different countries.11e18 In those studies, the
use of glycopeptides, extended-spectrum cephalosporins,
and fluoroquinolones was demonstrated to be associated
with the prevalence of MRSA and VRE.12e18 Few studies,
however, have investigated the relationship between the use
of linezolid or fusidic acid and the prevalence of MRSA and
VRE. In addition, the association between the consumption
of tigecycline, a novel anti-Gram-positive agent derived
fromminocycline that has been shown tobeeffective against
manyGram-negative rods aswell asGram-positive cocci, and
the prevalence of MRSA and VRE has never been studied.19
Similarly, no studies have so far investigated the associa-
tion between the prevalence of MRSA and VRE and the con-
sumption of daptomycin, an anti-MRSA antibiotic that has
been approved by the U.S. Food and Drug Administration for
the treatment of complicated skin and skin-structure in-
fections and bacteremia due to MRSA.20,21 In this study, we
investigated the correlation between consumption of anti-
biotics, including vancomycin, teicoplanin, linezolid, tige-
cycline, fusidic acid, and daptomycin, and the incidence ofHCAI-MRSA and HCAI-VRE during the period from 2000 to
2010 at a medical center in Taiwan.
Methods
Hospital setting
The National Taiwan University Hospital (NTUH) is a 2500-
bed, academically affiliated medical center that provides
both primary and tertiary care in northern Taiwan. The
number of annual inpatient-days at the hospital increased
from 624,675 in 2000 to 763,772 in 2010. Linezolid and fusidic
acid were introduced into the hospital formulary in 2002.
Tigecycline and daptomycin have been prescribed at the
NTUH since 2007 and 2009, respectively. Some of the data
analyzed in this study were included in a previous study.16,17
Bacterial isolates
Data on the susceptibilities of S. aureus to oxacillin were
collected during the period from 2000 to 2010. These isolates
were nonduplicate and isolates of each species from each
patient recovered within 7 days were considered as a single
isolate. Susceptibility testing for S. aureus and Enterococcus
species followed the Clinical and Laboratory Standards
Institute guidelines.22 S. aureus ATCC 25923 was used as the
control strain for routine disk-susceptibility testing.22
Methicillin resistance among S. aureus isolates was
routinely screened by measuring their growth on oxacillin
(6 mg/L) in 2% NaCl-containing trypticase soy agar plate that
had been incubated in ambient air at 35 C for 24 hours.22,23
Vancomycin resistance among Enterococcus species was
confirmed by growth of the isolate on a brain heart infusion
agar plate containing vancomycin (6 mg/L) that had been
incubated in ambient air at 35 C for 24 hours.22
Patients with HCAI-MRSA and HCAI-VRE
Yearly aggregated data on the number of nonduplicate
clinical MRSA and VRE isolates causing HCAI were collected.
HCAI was defined according to the National Nosocomial
Infection Surveillance guidelines.18 The incidence rates of
HCAI-MRSA and HCAI-VRE were defined as the number of
patients with HCAI-MRSA and HCAI-VRE, respectively, per
1000 inpatient-days.
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Antibiotic consumption and resistance 433Antimicrobial agents and consumption
Data on annual consumption [defined daily dose (DDD)/1000
inpatient-days] of glycopeptides (vancomycin and teico-
planin), linezolid, fusidic acid, tigecycline, and daptomycin
from 2000 to 2010 were obtained from the pharmacy
department of the hospital.0
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Linear regression analysis was used to analyze the trends in
annual consumption of antimicrobial agents and the trends
in incidence of HCAI-MRSA and HCAI-VRE over time. The
Pearson product moment correlation coefficient was used
to determine the relationship between annual antibiotic
consumption and trends in resistance. A p value < 0.05 was
considered statistically significant.0
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Figure 1. (A) Rates of methicillin-resistant Staphylococcus
aureus (MRSA) among S. aureus isolates causing health-care-
associated infection (HCAI) and the incidence (per 1000Results
Annual antibiotic consumption
In general, the use of each antimicrobial agent varied over
time (Table 1). Overall, the consumption of teicoplanin and
linezolid significantly increased, whereas the consumption
of vancomycin, glycopeptides (including vancomycin and
teicoplanin), tigecycline, and fusidic acid remained stable
during the study period.inpatient-days) of MRSA causing HCAI (HCAI-MRSA). (B) Rates of
vancomycin-resistant enterococci (VRE) among enterococcal
isolates causing HCAI and the incidence (per 1000 inpatient-
days) of VRE causing HCAI (HCAI-VRE).Trend in HCAI due to MRSA and VRE and the
incidence of HCAI-MRSA and HCAI-VRE during the
period 2000e2010
During the study period, a total of 4657 nonduplicate S.
aureus isolates and 4219 enterococcal isolates causing HCAI
were identified. Fig. 1A shows the trends in MRSA isolates
and incidence of HCAI-MRSA. There was a significant
decrease in the incidence of HCAI-MRSA over time. Fig. 1B
shows the trends in VRE isolates and the incidence of HCAI-
VRE. A significant rise in the incidence of HCAI-VRE over
time was noted.Table 1 Annual consumption of several antimicrobial agents at
Antimicrobial consumption (DDD
Year 2000 2001 2002 2003 2004 2005
Vancomycin 19.7 19.9 23.2 26.1 24.5 21.7
Teicoplanin 7.7 11.8 9.1 10.0 11.9 7.9
Glycopeptidesa 27.4 31.6 32.3 36.1 36.5 29.6
Linezolid 0.0 0.0 0.2 1.2 3.0 3.1
Fusidic acid 0.0 0.0 3.8 6.0 5.5 4.1
Tigecycline 0.0 0.0 0.0 0.0 0.0 0.0
Daptomycin 0.0 0.0 0.0 0.0 0.0 0.0
a Includes vancomycin and teicoplanin.
*Statistically significant association (p < 0.05).
DDD Z defined daily dose.Correlation between antibiotic consumption and
incidence of HCAI-MRSA and HCAI-VRE
Data on the correlation between the incidence of HCAI-
MRSA, the incidence of HCAI-VRE, and the annual con-
sumption of vancomycin, teicoplanin, linezolid, fusidic
acid, tigecycline, and daptomycin are shown in Tables 2
and 3. A significant correlation was found between thethe National Taiwan University Hospital, 2000e2010
/1000 patient-days) by year Trend analysis
2006 2007 2008 2009 2010 r p
20.1 19.1 20.9 18.1 17.8 0.477 0.138
9.0 10.1 11.7 13.1 14.5 0.619 0.042*
29.1 29.2 32.6 31.2 32.3 0.027 0.938
2.9 2.6 3.3 3.9 3.1 0.775 0.014*
3.6 4.9 4.8 2.7 3.0 0.57 0.109
0.0 1.8 3.7 5.0 6.0 0.847 0.153
0.0 0.0 0.0 1.2 3.0 d d
Table 3 Correlation between each antibiotic and the
density of health-care-associated infection due to
vancomycin-resistant Enterococcus species
Correlation
r p
Vancomycin 0.547 0.081
434 C.-C. Lai et al.increased use of linezolid and teicoplanin and the
decreased prevalence of MRSA. By contrast, no significant
correlation was found between the increased use of van-
comycin, glycopeptides (vancomycin and teicoplanin),
tigecycline, and fusidic acid and the incidence of HCAI-
MRSA. There was, however, a positive correlation be-
tween the incidence of HCAI-VRE and the use of teicoplanin
and tigecycline.Teicoplanin 0.758 0.007*
Glycopeptides 0.067 0.846
Linezolid 0.593 0.092
Tigecycline 0.976 0.024*
Fusidic acid 0.553 0.122
*Statistically significant association (p < 0.05).
r Z Pearson correlation coefficient.Discussion
This study evaluated the association between antibiotic
consumption and the incidence of HCAI-MRSA and HCAI-VRE
in a medical center in Taiwan during an 11-year period. .
analyzed the disease density (per 1000 patient-days) due to
resistant bacteria rather than resistance rate. This param-
eter (density) is now considered more appropriate to pre-
sent the real situation. In addition, we evaluated two newly
available antibiotics (tigecycline and daptomycin) and the
relationship with disease density. Using this new analysis
and adding some new data, we had several significant novel
findings.
We found that the consumption of teicoplanin and
linezolid significantly increased during the study period;
however, the consumption of vancomycin, glycopeptides
(both vancomycin and teicoplanin), and fusidic acid
remained stable. It is speculated that physicians in the
hospital are more likely to prescribe teicoplanin and line-
zolid than vancomycin for the treatment of MRSA infections
because teicoplanin and linezolid are associated with fewer
side effects, such as renal toxicity. In addition, the con-
sumption of tigecycline increased from 1.8 DDD/1000
inpatient-days in 2007 to 6.0 DDD/1000 inpatient-days in
2010. However, although the consumption of both tigecy-
cline and daptomycin increased over time, there was no
significant association between the consumption of those
antimicrobial agents and the incidence of nosocomial MRSA
infections during the study period. Long-term studies are
needed to evaluate the trend in HCAI-MRSA infections
associated with the consumption of tigecycline and
daptomycin.
Although the relationship between the incidence of
MRSA and the use of b-lactam antibiotics andTable 2 Correlation between each antibiotic and the
density of health-care-associated infection due to
methicillin-resistant Staphylococcus aureus
Correlation
r p
Vancomycin 0.594 0.054
Teicoplanin 0.700 0.017*
Glycopeptides 0.021 0.951
Linezolid 0.805 0.009*
Tigecycline 0.870 0.13
Fusidic acid 0.519 0.153
*Statistically significant association (p < 0.05).
r Z Pearson correlation coefficient.fluoroquinolones has been investigated,11e14,24 few studies
have focused on the association between consumption of
glycopeptides, linezolid, and fusidic acid and the incidence
of infection due to Gram-positive bacteria.16,17 In this
study, we found that the incidence of infections due to
MRSA significantly decreased from 0.6023/1000 inpatient-
days in 2000 to 0.2108/1000 inpatient-days in 2010. In
addition, we noted a negative correlation between the use
of teicoplanin and linezolid and the incidence of HCAI-
MRSA. Although further research is needed to clarify this
association, our findings suggest that teicoplanin and line-
zolid might exert a protective effect against the emergence
of MRSA. We also found that there was no significant cor-
relation between the consumption of vancomycin, glyco-
peptides including vancomycin and teicoplanin, and fusidic
acid and incidence of HCAI-MRSA, a finding that is consis-
tent with that reported in our previous study.17 In addition,
the consumption of tigecycline and daptomycin was not
associated with the incidence of HCAI-MRSA. The reason for
that finding is most likely due to the short duration of
tigecycline and daptomycin use in our hospital. A longer
study period is needed to clarify the correlation between
those two antimicrobial agents and the incidence of MRSA
infections.
Our data show that the incidence of HCAI-VRE signifi-
cantly increased during the study period. We found that the
increase in use of teicoplanin positively correlated with the
increase in incidence of HCAI-VRE. This finding is consistent
with that in our previous study.17 By contrast, we found
that there was a negative correlation between the use of
teicoplanin and the incidence of HCAI-MRSA. Our data also
show a positive correlation between the consumption of
tigecycline and the incidence of HCAI-VRE. Although tige-
cycline was used for only 4 years in this study, the strong
positive correlation between its use and the incidence of
VRE infections implies that tigecycline should be adminis-
tered with caution.
This study has several limitations. Although we found a
significant correlation between antibiotic use and the
incidence of HCAI-MRSA, the etiology behind the emer-
gence of drug-resistant bacteria in our hospital is compli-
cated and selective pressure from widespread use of
antimicrobial agents might be only one of the causes. The
prevalence of MRSA could have been affected by multiple
Antibiotic consumption and resistance 435factors such as infection-control measures and hand hy-
giene, or operational changes in the hospital. After the
emergence of severe acute respiratory syndrome in 2003,
the infection prevention and control program at the NTUH
was upgraded to include hand hygiene, antibiotic-control
policies, and an annual, intensive, project-based control
program. In fact, it has been demonstrated that those
policies are directly associated with the decrease in rates
of HCAIs and bloodstream infections at the NTUH.25 How-
ever, those effects were not measured in this study.
Whether those policies had an impact on MRSA trends re-
mains unknown. In addition, because this was an epidemi-
ological surveillance study, we did not analyze the impact
that duration of exposure to antibiotics, or clonal spread of
resistant bacteria had on the trend in incidence of noso-
comial MRSA infection. Furthermore, the overall DDD of a
given antibiotic is a notoriously problematic denominator as
there will be changes in low-dose usage in specific groups of
patients (i.e., children and patients with renal insuffi-
ciency). Therefore, an analysis using number of pre-
scriptions for those patient groups would be more
appropriate. However, the impact should be limited in this
study because those specific patient groups comprised only
a small fraction of the study patients and the effect would
be diluted and equal in each year.
In conclusion, in this 11-year study in a single medical
institution, we found that the use of teicoplanin and line-
zolid significantly increased. Furthermore, we found a
negative correlation between the usage of individual anti-
biotics, such as teicoplanin and linezolid, and the incidence
of HCAI-MRSA. However, we also found a positive correla-
tion between consumption of teicoplanin and tigecycline
and the incidence of HCAI-VRE. Therefore, strict imple-
mentation of infection-control policies including adminis-
tration of appropriate antimicrobial agents may be
positively correlated with a decrease in the presence of
MRSA in hospitals.
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